Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Delta radiomic parameters for the evaluation of liver metastases in patients with colorectal cancer treated with cetuximab rechallenge plus avelumab in the CAVE mCRC study.
Authors
Giulia Martini
Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy;
Giulia Martini , Valerio Nardone , Davide Ciardiello , Marco De Chiara , Teresa Troiani , Luca D'ambrosio , Stefania Napolitano , Claudia Cardone , Chiara Cremolini , Filippo Pietrantonio , Evaristo Maiello , Antonio Avallone , Salvatore Cappabianca , Fortunato Ciardiello , Alfonso Reginelli , Erika Martinelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 241)
DOI
10.1200/JCO.2023.41.4_suppl.241
Abstract #
241
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.
First Author: Qinmei Xu
Poster
2020 Gastrointestinal Cancers Symposium
The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy.
First Author: Laurent Dercle
Poster
2012 Gastrointestinal Cancers Symposium
CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab.
First Author: Dai Inoue
Poster
2024 ASCO Breakthrough
Utility of radiomic features in predicting clinical outcomes in stage II-III pancreatic cancer.
First Author: Haruka Itakura